Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer.
The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes.